-
National medical organizations have issued positions on adolescent care will impact your practice. Add the following to the next clinical discussion at your facility:
-
As of September 2010, federal health reform legislation will require all new private health plans to provide coverage of a slate of preventive health services at no cost to patients. Will contraception be included in that coverage? Reproductive health advocates are calling for such measures.
-
When it comes to unplanned pregnancy and sexually transmitted diseases (STDs), young women, adolescents, and the poor often are the most at risk. However, women from all socioeconomic groups face challenges to their sexual and reproductive health.
-
What will it take to stem the incidence of HIV in the United States? According to the Centers for Disease Control and Prevention (CDC), about 56,300 people were newly infected with HIV in 2006, the most recent year for which data are available.
-
Check for use of erectile dysfunction (ED) drugs among older male patients; a new analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases (STDs) than were non-users.
-
Adaora Adimora, MD, MPH, professor of medicine in the Division of Infectious Disease at the University of North Carolina School of Medicine in Chapel Hill, recently discussed her research on the nuances of HIV risk behavior among women with AHC Media, publisher of Contraceptive Technology Update.
-
American women might have another option in emergency contraception (EC) if the Food and Drug Administration (FDA) follows the recommendation of its reproductive health panel in approving ulipristal acetate (UPA).
-
Morbidities and mortalities among adolescents often are the result of risk-taking behaviors. By tracking behavioral trends, clinicians can provide more tailored education, counseling, and screenings to adolescents.
-
Fibrates: Generally safe, but do they improve outcomes?; Safety of testosterone replacement; Glucosamine and low back pain; Effects of allopurinol upon exercise in patients with angina; Is obesity a factor in asthma?; A new tool for treatment of plantar warts
-
Data for 64 HIV/HCV co-infected patients treated in a prospective study of pegylated IFN alpha + RBV were analyzed. IFN was administered at 180 mcg SQ/week and RBV was dosed at 800 mg daily for patients with HCV genotype 2 or 3 and 1,000-1,200 mg/day for the first 12 weeks in patients with genotype 1 or 4, then reduced to 800 mg/day until completion of therapy.
